CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

And I do have several favorite stocks that fit that description. My top growth stock to buy in November is one that I've ...

Intellia Therapeutics is featured in Cathie Wood's portfolio and has a high Wall Street price target. The company's leading candidates look somewhat promising, but one of them just hit a major setback ...

TG Therapeutics (NASDAQ: TGTX) will release its quarterly earnings report on Monday, 2025-11-03. Here's a brief overview for investors ahead of the announcement. Analysts anticipate TG Therapeutics to ...

AbbVie said on Friday the Trump administration was pushing for steeper cuts in this year's Medicare drug price negotiations, ...

Shares of CleanSpark, Inc. (NASDAQ:CLSK) are trading higher Wednesday after the Bitcoin (CRYPTO: BTC) miner announced ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Novartis is buying Avidity Biosciences in an all-cash deal valued at $12 billion to access Avidity's experimental treatments for neuromuscular diseases.

Intellia Therapeutics (NASDAQ:NTLA) stock tumbled 50% Monday after the company announced it has temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to a ...

Read on to learn why.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.